COMPASS Trial results suggest affirmative Penumbra;s approach to effective thrombectomy approach for acute ischemic stroke as part of the ADAPT (A DirectAspiration, First Pass Technique) approach.The trial an independent, prospective, multi-center randomized trial that showed the use of Penumbra’s aspiration system was non-inferior to stent retrievers for patients with acute ischemic stroke. The COMPASS Trial reaffirmed the results of two previous multi-center randomized controlled trials – Penumbra’s 3D Trial and the independent ASTER (Adapt versus StEntRetriever) Trial – demonstrating improvements in procedure and technique while maintaining a strong safety profile and 90-day clinical outcomes for Penumbra’s aspiration system. COMPASS is the first of the three randomized trials to study the company’s latest reperfusion catheter, ACE™68 with the Penumbra System.
J Mocco, M.D., M.S., vice chair of neurosurgery, director, Cerebrovascular Center, Icahn School of Medicine at Mount Sinai, New York stated “The COMPASS Trial met its primary objective, demonstrating that acute ischemic stroke patients treated with the ADAPT approach do not have inferior outcomes to those treated with a first-line stent retriever.”
52 percent of patients treated with Penumbra’s aspiration system achieved the primary endpoint of modified Rankin Score (mRS) 0-2 at 90 days compared with 49 percent of patients treated with stent retrievers. Final revascularization rates were also similar for the two study arms: 92 percent of patients treated with ADAPT using Penumbra’s aspiration system achieved mTICI 2b-3 revascularization compared to 89 percent with stent retrievers (p=0.54). Moreover, the percentage of patients achieving TICI 3 was 38 percent for the ADAPT arm and 29 percent in the stent retriever arm (p=0.15).
Image Source: Penumbra